trending Market Intelligence /marketintelligence/en/news-insights/trending/-nqXyc9a0Hafj0tgBgTxWg2 content esgSubNav
In This List

Collegium terminates opioid drug license agreement with BioDelivery

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Collegium terminates opioid drug license agreement with BioDelivery

Collegium Pharmaceutical Inc. is returning to BioDelivery Sciences International Inc. the U.S. rights to opioid drug Onsolis.

The companies entered a license and development agreement for the drug in May 2016, and have since been collaborating on the transfer of product manufacturing to a new supplier.

Collegium's decision to terminate the license involves its recent license agreement to commercialize Depomed Inc.'s Nucynta.

The termination will be effective March 8, 2018.